BCAB Stock Summary and Trading Ideas (Bioatla | NASDAQ:BCAB)

BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.

Bioatla trades on the NASDAQ stock market under the symbol BCAB.

As of December 16, 2025, BCAB stock price declined to $0.76 with 971,779 million shares trading.

BCAB has a beta of 2.34, meaning it tends to be more sensitive to market movements. BCAB has a correlation of 0.11 to the broad based SPY ETF.

BCAB has a market cap of $44.69 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, BCAB traded as high as $9.23 and as low as $.24.

The top ETF exchange traded funds that BCAB belongs to (by Net Assets): VTI, VXF.

BCAB has underperformed the market in the last year with a price return of -47.6% while the SPY ETF gained +13.6%. However, in the short term, BCAB had mixed performance relative to the market. It has outperformed in the last 3 months, returning +9.4% vs +3.0% return in SPY. But in the last 2 weeks, BCAB shares have been beat by the market, returning -4.0% compared to an SPY return of -0.2%.

BCAB support price is $.68 and resistance is $.86 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BCAB shares will trade within this expected range on the day.